• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The New Trends of Drug R&D Outsourcing in China and India 2012 Product Image

The New Trends of Drug R&D Outsourcing in China and India 2012

  • Published: September 2012
  • Region: China, India
  • 311 Pages
  • JZMed Inc

The report, “The New Trends of Drug R&D Outsourcing in China and India”, published by JZMed, Inc, a world renowned market research firm specialized in pharmaceutical and biotechnology industries, has conducted so far the most complete and comprehensive comparisons between China and India in drug R&D and the related service industries. It is designed to help readers gain a clear understanding of which country between China and India is better suitable for what type of R&D projects and what different but successful R&D outsourcing strategies global drug companies have been taking in each country.

The rises of China and India as two key emerging markets provide enormous opportunities to both multinational drug companies and professional outsourcing service providers. However, there are significant differences between these two countries, in particular in the areas related to drug R&D, which makes each country unique for certain types of drug R&D outsourcing activities. Although multinational drug companies now could have more choices than ever before, China and India each actually play different roles in the long value chain of drug R&D as READ MORE >

Scope of the Report

About Author

Executive Summary

- China and India: The two key emerging players of global drug R&D outsourcing
- Current experiences of Chinese and Indian companies in innovative drug R&D
- The new trends of drug discovery outsourcing in China and India
- The new trends of preclinical and toxicology research outsourcing in China and India
- The new trends of clinical development outsourcing in China and India
- Analysis of best strategies for drug R&D outsourcing in China and India

Chapter One - China and India: The Two Key Emerging Players of Global Drug R&D Outsourcing
Summary
1.1. Introduction
1.2. Current trends of global drug R&D outsourcing
1.2.1 Pressures currently faced by global drug companies
1.2.2 Current global drug R&D outsourcing trends
1. Current R&D outsourcing service demands by major pharma companies
2. Current R&D outsourcing service demands by small biotech companies
1.3. China and India: The two key pharmamerging markets
1.3.1 Fast growth history and still huge future growth potential of Chinese pharmaceutical market
1.3.2 Growth history and future growth potential of Indian pharmaceutical market
1.3.3 Attraction of still comparably-low costs of both labor and materials in China and India
1.4 China and India possess unique features attracting global pharma companies for outsourcing
1.5 Latest R&D activities of major pharma companies in China and India
1.5.1 Major pharma companies in China
1.5.2 Major pharma companies in India
1.6 Current states of Chinese and Indian CRO industries
1.6.1 Current state and market size of Chinese CRO industry
1. Current structural features of Chinese CRO industry
2. Overview of current service capabilities of Chinese CRO industry
3. Current market size of Chinese CRO industry
1.6.2 Current state and market size of Indian CRO industry
1. Current structural features of Indian CRO industry
2. Overview of current service capabilities of Indian CRO industry
3. Current market size of Indian CRO industry
1.6.3 Current market value of global CRO industry

Chapter Two - Current Experiences of Chinese and Indian Companies in Innovative Drug R&D
Summary
2.1 Introduction
2.2 Current states of biotechnology industry in China and India
2.2.1 Current state of Chinese biotech industry
2.2.2 Current state of Indian biotech industry
2.3 Current states of innovative drug R&D in China and India
2.3.1 Current state of innovative drug R&D in China
1. Current state of innovative drug R&D in China
2. Chinese government’s support and investment in innovative drug R&D
3. Funding sources for innovative drug R&D in China
4. Roles played by multinational drug companies in China drug R&D
5. Examples of multinational pharma/biotech companies collaborating with Chinese companies on innovative drug R&D
2.3.2 Current state of innovative drug R&D in India
1. Growth history of innovative drug R&D in India
2. Funding sources for innovative drug R&D in India
3. Roles played by multinational drug companies in India drug R&D
2.4 Current states and capabilities of biologic drug R&D in China and India
2.4.1 Current state and capabilities of biologic drug R&D in China
2.4.2 Current state and capabilities of biologic drug R&D in India
2.5 Key domestic players in China and India and their pipelines of innovative drugs
2.5.1 Examples of Chinese companies focusing on innovative drug R&D
2.5.2 Examples of Indian companies focusing on innovative drug R&D

Chapter Three - The New Trends of Drug Discovery Outsourcing in China and India
Summary
3.1 Introduction
3.2 Latest trends of global drug discovery outsourcing services
3.3 Current competitive landscape and market sizes of drug discovery outsourcing services in China and India
3.3.1 Current competitive landscape and market size of drug discovery outsourcing services in China
3.3.2 Current competitive landscape and market size of drug discovery outsourcing services in India
3.4 Current service capabilities and key players of Chinese and Indian drug discovery service CROs
3.4.1 Current service capabilities and key players of Chinese drug discovery service CROs
1. Overview of current service capabilities of Chinese CROs in drug discovery
2. Key players of Chinese CROs offering drug discovery services
3.4.2 Current service capabilities and key players of Indian drug discovery service CROs
1. Overview of current service capabilities of Indian CROs in drug discovery
2. Key players of Indian CROs in drug discovery services
3.5 Major pharma companies outsourcing drug discovery research to China and India - Current development trends
3.5.1 Major pharma companies outsourcing drug discovery research to China
3.5.2 Major pharma companies outsourcing drug discovery research to India
3.6 R&D-focused multinational biotech companies outsourcing drug discovery research to China and India
3.6.1 Small biotech companies outsourcing drug discovery research to China
3.6.2 Small biotech companies outsourcing drug discovery research to India
3.7 Growth potentials of Chinese and Indian drug discovery outsourcing service markets – Future outlook
3.7.1 Future growth outlook of China drug discovery outsourcing service market
3.7.2 Future growth outlook of India drug discovery outsourcing service market
3.8 Current states of genomics and proteomics research and outsourcing services in China and India
3.8.1 Current state of genomics and proteomics research and outsourcing services in China
1. Current service capabilities and key players of Chinese CROs in genomics and proteomics research
2. Multinational drug companies outsourcing genomics and proteomics research to China - Current development trends
3. Multinational companies outsourcing target identification and validation research to China
3.8.2 Current competitive landscape of genomics and proteomics research services in India
1. Current competitive landscape of genomics and proteomics research in India
2. Current service capabilities and key players of Indian CROs in genomics and proteomics research
3. Examples of multinational companies collaborating with Indian companies on genomics and proteomics research
3.8.3 Growth potentials of Chinese and Indian genomics and proteomics research service markets – Future outlook

Chapter Four - The New Trends of Preclinical and Toxicology Research Outsourcing in China and India
Summary
4.1 Introduction
4.2 Latest trends of global preclinical development and toxicology research outsourcing
4.3 Current competitive landscape and market sizes of preclinical development and tox research services in China and India
4.3.1 Current competitive landscape and market size of preclinical development and tox research services in China
4.3.2 Current competitive landscape and market size of preclinical development and tox research services in India
4.4 Current service capabilities and key players of Chinese and Indian CROs in preclinical development and tox research services
4.4.1 Current service capabilities and key players of Chinese CROs in preclinical development and tox research services
1. Current service capabilities of Chinese preclinical and tox research service CROs
2. Current facilities of Chinese preclinical research service CROs
3. Major Chinese CROs providing preclinical development and tox research services
4. Examples of multinational preclinical research service CROs in China
4.4.2 Current service capabilities and key players of Indian CROs in preclinical development and tox research services
4.5 Multinational companies outsourcing preclinical development and tox research to China and India ? Current development trends
4.5.1 Multinational companies outsourcing preclinical development and tox research to China – Current development trends
4.5.2 Multinational companies outsourcing preclinical development and tox research to India - Current development trends
4.6 Growth potentials of Chinese and Indian preclinical development and tox research service markets – Future outlook
4.6.1 Growth potential of Chinese preclinical development and tox research service market – Future outlook
4.6.2 Growth potential of Indian preclinical development and tox research service market – Future outlook

Chapter Five - The New Trends of Clinical Development Outsourcing in China and India
Summary
5.1 Introduction
5.2 Latest trends of global clinical trial outsourcing
5.3 Current competitive landscape and market sizes of clinical development services in China and India
5.3.1 Current competitive landscape and market size of clinical development services in China
5.3.2 Current competitive landscape and market size of clinical development services in India
5.4 Current regulatory states of clinical trial in China and India
5.4.1 Current regulatory state of clinical trial in China
5.4.2 Current regulatory state of clinical trial in India
5.5 Current service capabilities and key players of Chinese and Indian CROs in clinical trial services
5.5.1 Current service capabilities and key players of Chinese CROs in clinical trial services
1. Key Chinese CROs offering clinical trial services
2. Multinational clinical trial service CROs in China
5.5.2 Current service capabilities and key players of Indian CROs in clinical trial services
1. Key Indian CROs offering clinical trial services
2. Multinational clinical trial service CROs in India
5.6 Multinational drug companies outsourcing clinical trials to China and India- Current development trends
5.6.1 Multinational drug companies outsourcing clinical trials to China - Current development trends
1. Major pharma companies outsourcing clinical trials to China
2. Global biotech companies outsourcing clinical trials to China
5.6.2 Multinational drug companies outsourcing clinical trials to India - Current development trends
5.7 Growth potentials of Chinese and Indian clinical trial service markets – Future outlook
5.7.1 Growth potential of Chinese clinical trial service market – Future outlook
5.7.2 Growth potential of Indian clinical trial service market – Future outlook
5.8 Current states of bioanalytical services in China and India
5.8.1 Bioanalytical services in China
5.8.2 Bioanalytical services in India

Chapter Six - Analysis of Best Strategies for Drug R&D Outsourcing in China and India
Summary
6.1 Introduction
6.2 General comparisons of pharmaceutical industry between China and India
6.2.1 Comparison of general industrial infrastructure between China and India
1. General industrial infrastructure in China
2. General industrial infrastructure in India
6.2.2 Comparison of business philosophy between Chinese companies and Indian companies
1. Chinese business philosophy
2. Indian business philosophy
6.2.3 Comparison of workforce structure in pharmaceutical industry between China and India
1. Workforce structure of Chinese pharmaceutical industry
2. Workforce structure of Indian pharmaceutical industry
6.2.4 Comparison of current labor and raw material costs in pharmaceutical industry between China and India
6.3 Comparisons of biotechnology industry between China and India and in-depth analysis of their future development prospects
6.4 Comparison of innovative drug R&D between China and India and in-depth analysis of their future development prospects
6.5 In-depth analyses and comparisons of drug R&D outsourcing service industry between China and India
6.5.1 Comparison of service capabilities between China and India in target identification and validation
6.5.2 Comparison of drug discovery service capabilities between China and India
6.5.3 Comparison of service capabilities between China and India in preclinical and tox research services
6.5.4 Comparison of service capabilities between China and India in clinical trials
6.5.5 Current performances of multinational clinical trial service CROs in China and India
6.5.6 Local domestic major pharma companies’ roles in drug R&D outsourcing services in each country
6.5.7 Conclusions
6.6 Analysis of different R&D strategies of major pharma companies in China and India
6.6.1 Major pharma’s China R&D strategies
6.6.2 Major pharma’s India R&D strategies
6.7 Analysis of different outsourcing strategies of major pharma companies in China and India
6.8 Comparison of future growth potentials of drug R&D outsourcing service markets between China and India
6.9 Analysis of future growth obstacles of Chinese and Indian CRO industry
6.9.1 Fast rising labor cost
6.9.2 Weak service capabilities
6.9.3 Low service demands by local drug companies
6.9.4 Less robust regulatory systems
6.9.5 Competitions from other Asian countries

Appendix

Appendix I. Research Methodology

Appendix II. About JZMed, Inc.

List of Tables

Table 1. Advantages of outsourcing
Table 2. Pressures currently facing global pharmaceutical industry
Table 3. FDA’s approval rates of new drugs in recent six years
Table 4. Statistic distribution of failure rates in each development stage of drug R&D
Table 5. Factors contributing to high failure rates in drug development
Table 6. Factors negatively affecting the sustainability of traditional pharmaceutical operating model
Table 7. R&D service areas currently most desired by major pharma companies
Table 8. New outsourcing trends after financial crisis
Table 9. Common attractive features China and India both possess
Table 10. Unique advantages (resources) China and India currently possess over other developing countries
Table 11. Development history, current market size and future growth forecast of the Western-style medicines in Chinese pharmaceutical market
Table 12. Current market value and growth history of Indian pharmaceutical market
Table 13. Comparison of labor costs (FTE rates) in various locations of the world
Table 14. Key advantages of China and India over developed countries
Table 15. Benefits of global drug companies entering Chinese and Indian markets
Table 16. Current activities of global major pharma companies in Chinese market
Table 17. R&D outsourcing development trends of major pharma in China
Table 18. Current market value and past growth history of Chinese CRO industry
Table 19. Current market value and past growth history of Indian CRO industry
Table 20. Current market value and past growth history of global CRO industry
Table 21. Analysis of new trends evolving in global pharma outsourcing industry
Table 22. Current structural composition of Chinese biotech industry
Table 23. Current structural composition of Indian biotech industry
Table 24. Comparison of biologic product markets between China and India
Table 25. Current state of Indian biotech industry
Table 26. Drivers forcing China to be determined to increase investment in and focus on R&D for new medicines
Table 27. R&D strategies currently practiced by Chinese biotech companies
Table 28. Analysis of licensing deals between multinational drug companies and Chinese companies
Table 29. Current R&D pipelines of innovative drugs in China
Table 30. Growth trends of Chinese government’s investment in innovative drug R&D and comparison with R&D investment of Indian government
Table 31. Major pharma companies having corporate venture investment offices in China
Table 32. Growth trend of VC investments in Chinese life science industries
Table 33. Funding sources for innovative drug R&D in China
Table 34. Major pharma companies having (or planning to have) Asia-Pacific operating (or R&D) headquarters in China
Table 35. Current key forces in India’s innovative drug R&D efforts
Table 36. Chinese companies conducting innovative drug R&D and their product pipelines
Table 37. Chinese companies conducting clinical trials in regulated countries
Table 38. Current pipelines of novel drugs under development in some major Indian pharma companies
Table 39. Current R&D spending breakdown by research activities
Table 40. Current growth drivers of Chinese drug discovery outsourcing service market
Table 41. Small molecule drug discovery outsourcing in China approaching mature
Table 42. Current market value and past growth history of Chinese drug discovery outsourcing services
Table 43. Analysis on growth slowdown of drug discovery outsourcing in India
Table 44. Current market value and past growth history of Indian drug discovery outsourcing services
Table 45. Representative Chinese CROs offering drug discovery services (Including their service capabilities and contact information)
Table 46. Representative Indian CROs offering drug discovery services (Including their service capabilities and contact information)
Table 47. Multinational CROs entering India to offer drug discovery services
Table 48. Examples of major partnerships forged in the recent years between major pharma companies and Indian companies on drug discovery research
Table 49. Common outsourcing models of multinational biotech companies in China
Table 50. Analysis of future growth opportunities in China drug discovery services
Table 51. Forecasted future growth of Chinese drug discovery service market
Table 52. Forecasted future growth of global drug discovery service market
Table 53. Growth drivers of Indian drug discovery service market
Table 54. Forecasted future growth of Indian drug discovery service market
Table 55. Genomics and proteomics research services currently available in China
Table 56. Representative Chinese companies providing genomics and proteomics research services (Including their service capabilities and contact information)
Table 57. Latest examples of collaboration between Chinese organizations and multinational companies on development of biomarkers and/or molecular diagnostics in China
Table 58. Examples of multinational companies collaborating with Chinese organizations on target identification and validation
Table 59. Representative Indian CROs providing genomics and proteomics research services (Including their service capabilities and contact information)
Table 60. Current market value and future growth forecast of genomics and proteomics research services in China and comparisons with its Indian counterparts
Table 61. Forecasted future growth of global genomics and proteomics research service market
Table 62. Factors affecting the current low demands for global preclinical development and tox research services
Table 63. China’s advantages in preclinical development and toxicology research
Table 64. Analysis of current slow growth of Chinese preclinical and tox research service market
Table 65. Potential hurdles facing future growth of Chinese preclinical and tox research service market
Table 66. China-based CROs (or research organizations) accredited by AAALAC
Table 67. Representative Chinese CROs providing preclinical development and tox research services (Including their service capabilities and contact information)
Table 68. Representative Indian CROs providing preclinical development and tox research services (Including their service capabilities and contact information)
Table 69. Market growth forecast of Chinese preclinical development and tox research services
Table 70. Market growth forecast of global preclinical development and tox research services
Table 71. Market growth forecast of Indian preclinical development and tox research services and comparison with its Chinese counterpart
Table 72. Attractions of Asia Pacific region for global clinical trials
Table 73. Factors causing clinical trials so difficult
Table 74. New developments in global clinical trials
Table 75. Comparisons of patient recruiting time and site setup time between China and India
Table 76. Current market value and past growth history of clinical trial services in China
Table 77. Growth trend of clinical trials conducted in India and its comparison with China
Table 78. Comparison of clinical trial cost between China and India
Table 79. Current market value and past growth history of clinical trial service in India
Table 80. Comparisons of current clinical trial approval time between China and India
Table 81. Past five-year death incidents in clinical trials in India
Table 82. Representative Chinese CROs offering clinical trial services (Including their service capabilities and contact information)
Table 83. Representative Indian CROs offering clinical trial services (Including their service capabilities and contact information)
Table 84. More examples of multinational clinical trial service CROs establishing presences in India or forming partnerships with Indian counterparts
Table 85. Drivers and resistors for future growth of Chinese clinical trial service market
Table 86. Other factors positively driving the future growth of Chinese clinical trial service market
Table 87. Forecasted future growth of Chinese clinical trial service market
Table 88. Growth drivers of Indian clinical trial service market
Table 89. Forecasted future growth of Indian clinical trial service market
Table 90. Forecasted future growth of global clinical trial service market
Table 91. Comparison of service scope between traditional bioanalysis and modern bioanalysis
Table 92. Bioanalytical services currently available in China
Table 93. Representative Chinese CROs providing bioanalytical services (Including their service capabilities and contact information)
Table 94. Bioanalytical services currently available in India
Table 95. Representative Indian CROs providing bioanalytical services (Including their service capabilities and contact information)
Table 96. Common goals of major pharma companies in China and India
Table 97. Comparison of technical workforces in pharma-related industries between China and India
Table 98. Comparison of current labor and material costs in pharmaceutical industry between China and India
Table 99. Criteria to consider when outsourcing to China and/or India
Table 100. Current shortcomings of Chinese biotech industry
Table 101. Comparison of overall capabilities of biotech industry between China and India
Table 102. Comparison of future growth drivers and resistors of biotech industry between China and India
Table 103. Comparison of current key innovative drug R&D forces between China and India
Table 104. Current drawbacks causing the slow development of innovative drug R&D in India
Table 105. Analysis of development path of India innovative drug R&D and lessons China could learn from
Table 106. Analysis and comparison of long term development prospects of innovative drug R&D between China and India
Table 107. Hurdles for effectively conducting clinical trials in China
Table 108. Analysis of causes of low operating efficiency of some multinational CROs in emerging markets
Table 109. Head-to-head comparison of advantages and disadvantages between China and India in pharma-related industries
Table 110. Comparison of drug R&D outsourcing service capabilities between China and India
Table 111. Criteria for effectively selecting an ideal service provider in China or India
Table 112. Analysis of best outsourcing strategies in China and India
Table 113. Elements required for effectively conducting innovative drug R&D in a country
Table 114. Motivations of major pharma companies’ R&D activities in China
Table 115. China is ready to play important roles in global drug R&D
Table 116. Analysis of different investment strategies of major pharma companies in China and India
Table 117. Common growth drivers of Chinese and Indian CRO market
Table 118. Forecasted future growths of Chinese, Indian and global CRO markets
Table 119. Analysis of future development trends of Chinese and Indian CRO industries
Table 120. Analysis of weak points in future growth of Chinese clinical trial service market
Table 121. Common challenges conducting clinical trials in China and India (and any other emerging markets)

List of Figures

Figure 1. Changes of ranking of Chinese pharmaceutical market in global market in past decade
Figure 2. Changes of ranking of Indian pharmaceutical market in global market in past decade
Figure 3. An overview of current state of Chinese pharma outsourcing industry
Figure 4. Growth trends of Chinese CRO market in past five years
Figure 5. Current customer distributions of Chinese CROs
Figure 6. An overview of current state of Indian pharma outsourcing industry
Figure 7. Growth trends of Indian CRO market in past five years
Figure 8. Current customer distributions of Indian CROs
Figure 9. Growth trends of global CRO market in past five years
Figure 10. Analysis of structural compositions of Chinese biotech industry
Figure 11. Analysis of structural compositions of Indian biotech industry
Figure 12. Comparison of growth trends of biologic product market between China and India
Figure 13. Growth trends of Chinese drug R&D pipelines
Figure 14. Description of the value chain of drug discovery and development
Figure 15. Growth trends of Chinese drug discovery outsourcing service market in past five years
Figure 16. Growth trends of Indian drug discovery outsourcing service market in past five years
Figure 17. Forecasted future growth trend of Chinese drug discovery outsourcing service market
Figure 18. Forecasted future growth trend of global drug discovery outsourcing service market
Figure 19. Forecasted future growth trend of Indian drug discovery outsourcing service market
Figure 20. Forecasted market growth trends of genomics and proteomics research services in India and China
Figure 21. Forecasted market growth trend of global genomics and proteomics research services
Figure 22. Forecasted market growth trend of Chinese preclinical development and tox research services
Figure 23. Forecasted market growth trend of global preclinical development and tox research services
Figure 24. Forecasted market growth trend of Indian preclinical development and tox research services
Figure 25. Past growth trend of Chinese clinical trial service market
Figure 26. Past growth trend of Indian clinical trial service market
Figure 27. Forecasted future growth trend of Chinese clinical trial service market
Figure 28. Forecasted future growth trend of Indian clinical trial service market
Figure 29. Forecasted future growth trend of global clinical trial service market
Figure 30. Forecasted future growth trends of Chinese and Indian CRO markets

List of Case Studies

Case Study 1. Drug R&D would not have been that costly if failure rate could be reduced
Case Study 2. More R&D-focused biotech companies adopting virtual operation model
Case Study 3. Shantha Biotechics
Case Study 4. Major pharma companies licensing drug candidates to Chinese drug companies for co-development in China
Case Study 5. More examples of recent licensing/co-development deals between multinational drug companies and Chinese companies
Case Study 6. Examples of Chinese R&D-focused biotech companies founded by successful Chinese businessmen in other industries
Case Study 7. Growing abundance of various funding opportunities for Chinese biotech companies to conduct innovative drug R&D
Case Study 8. Examples of international venture capital investors interested in Chinese life science industry
Case Study 9. Major pharma companies partnering with Chinese companies on drug R&D
Case Study 10. Multinational biotech companies conducting drug R&D in China
Case Study 11. Multinational biotech companies acquiring Chinese drug developers
Case Study 12. More examples of multinational drug companies collaborating with Chinese organizations on drug R&D
Case Study 13. R&D development path of Dr. Reddy’s Lab
Case Study 14. Major pharma companies collaborating with Indian companies on drug R&D
Case Study 15. Non-profit organizations partnering with Indian organizations to conduct drug R&D in India for India
Case Study 16. Chinese companies focusing on mAb drugs
Case Study 17. R&D capability of a typical Chinese biopharma company
Case Study 18. Examples of R&D approaches of Chinese biopharma companies in discovering innovative biologic drugs
Case Study 19. Examples of Indian biopharma companies’ capability in biosimilar R&D
Case Study 20. Long term collaboration between BMS and Syngene on drug discovery and development
Case Study 21. Examples of major pharma companies collaborating with Chinese organizations for natural product libraries
Case Study 22. Analysis of current service capabilities of WuXi PharmaTech
Case Study 23. Indian CROs partnering with multinational CROs to offer integrated drug discovery services
Case Study 24. Indian CROs enhancing their service capabilities in drug discovery by licensing technologies from companies in developed countries
Case Study 25. AstraZeneca contracting out drug discovery research to Chinese CROs
Case Study 26. Major pharma companies outsourcing comprehensive drug discovery research to China-based CROs
Case Study 27. Major pharma companies showing greater interests in partnering with Asian organizations
Case Study 28. Curis with ShangPharma ? To stretch the dollar value of cash reserve by allocating part of drug R&D program to China
Case Study 29. More examples of small biotech companies outsourcing drug discovery research to China
Case Study 30. Pharma company’s virtual drug discovery research strategy
Case Study 31. Merck collaborating with BGI on biomarker and genomic research
Case Study 32. GVK Biosciences possessing biomarker database
Case Study 33. Examples of collaboration between Indian CROs and Western CROs on genomics and proteomics research
Case Study 34. Multinational preclinical service CROs in China
Case Study 35. Examples of Indian CROs’ capabilities in preclinical development and toxicology research services
Case Study 36. Multinational CROs partnering with Indian CROs to offer preclinical research services in India
Case Study 37. Examples of multinational drug companies outsourcing preclinical development and tox research to China
Case Study 38. Examples of multinational pharma companies outsourcing preclinical development and tox research to India
Case Study 39. More examples of multinational clinical trial service CROs in China
Case Study 40. Latest activities of Indian CROs strengthening their service capabilities in clinical development
Case Study 41. Roche’s clinical trial outsourcing strategies in China
Case Study 42. Pfizer increasing clinical trials in China
Case Study 43. Examples of global biotech companies conducting clinical trials in China
Case Study 44. Examples of global biotech companies conducting clinical trials in India
Case Study 45. Strategies of Quiagen in China and India
Case Study 46. Analysis of impacts of fast rising labor cost in China on Chinese pharma outsourcing industry
Case Study 47. Technical capabilities of Chinese life science industry on the rise
Case Study 48. Collaboration between Chinese biopharma companies and Indian counterparts for development of biosimilars
Case Study 49. India taking actions to train its clinical trial personnel
Case Study 50. More major pharma deciding to move R&D centers from the West to China
Case Study 51. Major pharma deciding to establish full-scale R&D centers in China
Case Study 52. Major pharma de-risking drug R&D in China
Case Study 53. Major pharma licensing drug candidates from Chinese biotech companies
Case Study 54. Merck Serono forming close partnership with Dr. Reddy’s Lab on co-development of biosimilars
Case Study 55. Sign of major pharma moving R&D out of India and increasing investments in China

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos